An update on the pharmacotherapy for lower urinary tract dysfunction

Bibliography

• Chancellor MB, Yoshimura N. Physiology and pharmacology of the bladder and urethra. In: Alan JW, Louis RK, Andrew CN, Alan WP, Craig AP, editors. Campbell’s urology. 8th edition. Saunders, Philadelphia, PA, USA
   Google Scholar
• Cipullo L, Zullo F, Cosimato C, et al. Pharmacological treatment of urinary incontinence. Female Pelvic Med Reconstr Surg 2014;20(4):185-202
   PubMed Web of Science ®Google Scholar
• Andersson KE, Wein A. Pharmacologic management of lower urinary tract storage and emptying failure. In: Alan JW, Louis RK, Andrew CN, Alan WP, Craig AP, editors. Campbell’s urology. 10th edition. Saunders, Philadelphia, PA, USA
   Google Scholar
• Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurouruol Urodyn 2011;30(3):292-301
   PubMed Web of Science ®Google Scholar
• Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurouruol Urodyn 2010;29:4-20
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Bell JA, et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurouruol Urodyn 2013;32(3):230-7
   PubMed Web of Science ®Google Scholar
• Rai BP, Cody JD, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev 2012;12:CD003193
   PubMedGoogle Scholar
• Krause P, Fuhr U, Schnitker J, et al. Pharmacokinetics of intravesical versus oral oxybutynin in healthy adults: results of an open label, randomized, prospective clinical study. J Urol 2013;190(5):1791-7
   PubMed Web of Science ®Google Scholar
• Nabi G, Cody JD, Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006(4):CD003781
   Google Scholar
• Natalin R, Lorenzetti F, Dambros M. Management of OAB in those over age 65. Curr Urol Rep 2013;14(5):379-85
   Google Scholar
• Reiz JL, Salem P, Darke AC. Pharmacokinetics and pharmacodynamics of once-daily controlled-release oxybutynin and immediate release oxybutynin. J Clin Pharmacol 2007;47(3):351-7
   Google Scholar
• Gittelman M, Weiss H, Seidman L. A phase 2, randomized, double-blind, efficacy and safety study of oxybutynin vaginal ring for alleviation of overactive bladder symptoms in women. J Urol 2014;191(4):1014-21
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Staskin DR, Duchin K, et al. Clinical safety, tolerability and efficacy of combination tolterodine/pilocarpine in patients with overactive bladder. Int J Clin Pract 2014(8):986-94
   Google Scholar
• Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract 2010;64(9):1294-300
   PubMed Web of Science ®Google Scholar
• Cvijic S, Langguth P. Improvement of trospium-specific absorption models for fasted and fed states in humans. Biopharm Drug Dispos 2014. [ Epub ahead of print]
   Google Scholar
• Haupt M, Thommes M, Heidenreick A, et al. Lipid-based intravesical drug delivery systems with controlled release of trospium chloride for the urinary bladder. J Control Release 2013;170(2):161-6
   Google Scholar
• Ginsberg D, Schneider T, Kelleher C, et al. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. BJU Int 2012;12(3):373-85
   Google Scholar
• DuBeau CE, Kraus SR, Griebling TL, et al. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial. J Urol 2014;191(2):395-404
   PubMed Web of Science ®Google Scholar
• Wagg A, Dale M, Tretter R, et al. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013;64(1):74-81
   PubMed Web of Science ®Google Scholar
• Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II Open-label Extension. Eur Urol 2014. [ Epub ahead of print]
   Web of Science ®Google Scholar
• Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012;1:CD005429
   PubMedGoogle Scholar
• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline. J Urol 2012;188(6 Suppl):2455-63
   PubMed Web of Science ®Google Scholar
• Sears CL, Lewis C, Noel K, et al. Overactive bladder medication adherence when medication is free to patients. J Urol 2010;183(3):1077-81
   PubMed Web of Science ®Google Scholar
• Veenboer PW, Ruud Bosch JL. Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review. J Urol 2014;191:1003-8
   PubMed Web of Science ®Google Scholar
• Roxburgh C, Cook J, and Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2007(3):CD003190
   Google Scholar
• Andersson KE, Martin N, Nitti V. Selective beta3-Adrenoreceptor agonists for the treatment of overactive bladder. J Urol 2013;90(4):1173-80
   Google Scholar
• Takusagawa S, Miyashita A, Iwatsubo T, et al. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective beta3-adrenoreceptor agonist. Xenobiotica 2012;42(12):1187-96
   PubMed Web of Science ®Google Scholar
• Wu T, Duan X. Cao Cx, et al. The role of mirabegron in overactive bladder: a systematic review and meta-analysis. Urol Int 2014;93(3):326-37
   PubMed Web of Science ®Google Scholar
• Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2014;65(4):755-65
   PubMed Web of Science ®Google Scholar
• Steers WD, Herschorn S, Kreder KJ, et al. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int 2007;100(2):337-45
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomized, double-blind, dose-ranging, Phase 2 study (Symphony). Eur Urol 2014. [ Epub ahead of print]
   Google Scholar
• Osman NI, Chapple C, Abrams P, et al. Detrusor underactivity and the underactive bladder: a new clinical entity? A review of current terminology, definitions, epidemiology, aetiology, and diagnosis. Eur Urol 2014;65(2):389-98
   PubMed Web of Science ®Google Scholar
• Barendrecht MM, Oelke M, Laguna MP. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int 2007;99(4):749
   PubMed Web of Science ®Google Scholar
• Yamanishi T, Yasuda K, Kamai T, et al. Combination of a cholinergic drug and alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int J Urol 2004;11(2):88
   PubMed Web of Science ®Google Scholar
• Chang SJ, Chiang IN, Yu HJ. The effectiveness of tamsulosin in treating women with voiding difficulty. Int J Urol 2008;15(11):981
   PubMed Web of Science ®Google Scholar
• Abraham N, Goldman H. Detrusor Underactivity. AUA Update Series 2014. Volume 33. Lesson 11. American Urological Association, Linthicum, MD, USA
   Google Scholar
• Dmochowski RR, Blaivas JM, Gormley EA, et al. Update of AUA guideline on the surgical management of female stress urinary incontinence. J Urol 2010;183(5):1906-14
   PubMed Web of Science ®Google Scholar
• Alhasso A, Glazener CM, Pickard R, N’Dow J. Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev 2005(3):CD001842
   Google Scholar
• Robinson D, Abrams P, Cardozo L, et al. The efficacy and safety of PSD503 (phenylephrine 20%, w/w) for topical application in women with stress urinary incontinence. A phase II, multicentre, double-blind, placebo controlled, 2-way cross over study. Eur J Obstet Gynecol Reprod Biol 2011;159(2):457-60
   Google Scholar
• Tsakiris P, de la Rosette JJ, Michel MC, et al. Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence. Eur Urol 2008;53(1):53-9
   Google Scholar
• Gilja I, Radej M, Kovacic M, et al. Conservative treatment of female stress incontinence with imipramine. J Urol 1984;132:909-11
   PubMed Web of Science ®Google Scholar
• Lin HH, Sheu BC, Lo MC, et al. Comparison of treatment outcomes for imipramine for female genuine stress incontinence. Br J Obstet Gynaecol 1999;106:1089-92
   Google Scholar
• Reid GF, Fitzpatrick JM, Worth PH. The treatment of patients with urinary incontinence after prostatectomy. Br J Urol 1980;52:532-4
   Google Scholar
• Mariappan P, Alhasso AA, Grant A, et al. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database Syst Rev 2005(3):CD004742
   Google Scholar
• Schwertner-Teipelmann N, Schwab F, Tunn R. Do predictive parameters exist for therapy with duloxetine in women with stress urinary incontinence? Int Urogynecol J 2014;25:1071-9
   Google Scholar
• Padmanabhan P, Rosenblum N. Chapter 16: Idiopathic urinary retention in the female. In: Raz S, Rodriguez L, editors. Female urology. Elsevier, Philadelphia, PA, USA; 2008
   Google Scholar
• Chatziralli IP, Sergentanis TN. Risk factors for intraoperative floppy iris syndrome: a meta-analysis. Ophthalmology 2011;118:730-5
   PubMed Web of Science ®Google Scholar
• Wilt T, Howe RW, Rutks I, et al. Terazosin for benign prostatic hyperplasia. Cochrane Database of Syst Rev 2000(1):CD003851
   Google Scholar
• Wilt T, MacDonald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database of Syst Rev 2003(1):CD002081
   Google Scholar
• Tacklind J, Fink HA, Macdonald R, et al. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev 2010(10):CD006015
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Barkin J, Tubaro A, et al. Influence of baseline variables on changes in s combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int 2014;113(4):623-35
   Google Scholar
• Gacci M, Coronoa G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61(5):994-1003
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
   PubMed Web of Science ®Google Scholar